CA2008772A1 - Oral antifungal preventative, and method of use - Google Patents
Oral antifungal preventative, and method of useInfo
- Publication number
- CA2008772A1 CA2008772A1 CA 2008772 CA2008772A CA2008772A1 CA 2008772 A1 CA2008772 A1 CA 2008772A1 CA 2008772 CA2008772 CA 2008772 CA 2008772 A CA2008772 A CA 2008772A CA 2008772 A1 CA2008772 A1 CA 2008772A1
- Authority
- CA
- Canada
- Prior art keywords
- varnish composition
- oral
- composition
- group
- varnish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 70
- 210000000214 mouth Anatomy 0.000 claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims abstract description 30
- 238000013268 sustained release Methods 0.000 claims abstract description 23
- 239000012730 sustained-release form Substances 0.000 claims abstract description 23
- 229920000642 polymer Polymers 0.000 claims abstract description 21
- 239000000853 adhesive Substances 0.000 claims abstract description 6
- 230000001070 adhesive effect Effects 0.000 claims abstract description 6
- 239000004014 plasticizer Substances 0.000 claims abstract description 6
- 239000002966 varnish Substances 0.000 claims description 34
- 239000003429 antifungal agent Substances 0.000 claims description 31
- 229960000988 nystatin Drugs 0.000 claims description 19
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 19
- 239000001856 Ethyl cellulose Substances 0.000 claims description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 241000222122 Candida albicans Species 0.000 claims description 9
- 208000006819 Denture Stomatitis Diseases 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920000175 Pistacia lentiscus Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229960003942 amphotericin b Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 3
- -1 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims description 2
- 241000222126 [Candida] glabrata Species 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000009469 supplementation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 229940079593 drug Drugs 0.000 description 23
- 238000011282 treatment Methods 0.000 description 20
- 210000000515 tooth Anatomy 0.000 description 17
- 201000003984 candidiasis Diseases 0.000 description 14
- 238000009472 formulation Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 240000005428 Pistacia lentiscus Species 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000001857 anti-mycotic effect Effects 0.000 description 6
- 239000002543 antimycotic Substances 0.000 description 6
- 241000233866 Fungi Species 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 208000007027 Oral Candidiasis Diseases 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 239000013521 mastic Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 235000010603 pastilles Nutrition 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010007134 Candida infections Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010048685 Oral infection Diseases 0.000 description 3
- 241000287411 Turdidae Species 0.000 description 3
- 239000012871 anti-fungal composition Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000007406 plaque accumulation Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 201000000674 African histoplasmosis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 201000003950 Geotrichosis Diseases 0.000 description 1
- 244000168141 Geotrichum candidum Species 0.000 description 1
- 235000017388 Geotrichum candidum Nutrition 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical group CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- CANCCLAKQQHLNK-LSDHHAIUSA-N O-[[(1R,8S)-4-tricyclo[6.2.1.02,7]undeca-2(7),3,5-trienyl]] N-methyl-N-(3-methylphenyl)carbamothioate Chemical compound CN(C(=S)Oc1ccc2[C@H]3CC[C@H](C3)c2c1)c1cccc(C)c1 CANCCLAKQQHLNK-LSDHHAIUSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010061324 Oral fungal infection Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 241000022563 Rema Species 0.000 description 1
- 241000223667 Rhinocladiella Species 0.000 description 1
- 241000293824 Rhinosporidium seeberi Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 108010077913 Triamcinolone Acetonide Drug Combination Nystatin Neomycin Sulfate Gramicidin Proteins 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960003093 antiseptics and disinfectants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 150000004010 onium ions Chemical class 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229960003916 tolciclate Drugs 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ABSTRACT
The invention relates to an oral composition for preven-tion of mycotic infections of the oral cavity comprising an antifungal compound embedded in a sustained release carrier such as a cellulosic polymer, and a method for the use of said composition in preventing microfungal infections in the oral cavity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase antifungal effectiveness.
A104-10.WP 011090 ja001-02.ap
The invention relates to an oral composition for preven-tion of mycotic infections of the oral cavity comprising an antifungal compound embedded in a sustained release carrier such as a cellulosic polymer, and a method for the use of said composition in preventing microfungal infections in the oral cavity. The invention also provides for the supplementation of said oral composition with an adhesive and a plasticizer to increase antifungal effectiveness.
A104-10.WP 011090 ja001-02.ap
Description
38~7~7;~
TITLE OF THE INVENTION:
ORAL ANTIFUNGAL PREVENTATIVE, AND METHOD OF USE
FIELD OF THE INVENTION
The invention is directed to an antimycotic composition for the prevention of microfungal infections of the oral cavity and to a method for using said composition in tre~ting mycotic diseases of the oral cavity caused by microfungi.
OROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of United States Patent Application Serial` No. 07/304,092 (filed on January 31, 1989).
BACKGROUND OF THE INVENTION
Microfungi can be classified as yeasts and filamentous fungi. M;crofungi are capable of causing a variety of diseases in the oral cavity and the surrounding area. Mycotic diseases may arise as part of a systemic microfungal infection or may be derived from an independent infection which establ;shes in the oral cavity. Oral mycoses and their treatment are an important problem in oral medicine and have been reviewed in Kostiala, I. t al., Acta Odontol. Scand.
37:87-101 (1987), incorporated herein by reference.
TITLE OF THE INVENTION:
ORAL ANTIFUNGAL PREVENTATIVE, AND METHOD OF USE
FIELD OF THE INVENTION
The invention is directed to an antimycotic composition for the prevention of microfungal infections of the oral cavity and to a method for using said composition in tre~ting mycotic diseases of the oral cavity caused by microfungi.
OROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of United States Patent Application Serial` No. 07/304,092 (filed on January 31, 1989).
BACKGROUND OF THE INVENTION
Microfungi can be classified as yeasts and filamentous fungi. M;crofungi are capable of causing a variety of diseases in the oral cavity and the surrounding area. Mycotic diseases may arise as part of a systemic microfungal infection or may be derived from an independent infection which establ;shes in the oral cavity. Oral mycoses and their treatment are an important problem in oral medicine and have been reviewed in Kostiala, I. t al., Acta Odontol. Scand.
37:87-101 (1987), incorporated herein by reference.
-2- ~g~08~7~
Many factors can predispose a patient to an opportunistic microfungal infection in the oral cavity. For example, general debilitation or poor oral hyg;ene are predisposing factors. Patients who are being treated with antibiotics, steroids, or cytostatic therapy, patients with AIDS, diabetes mellitus or other immunodeficiency or hormonal diseases, patients with malignant tumors or a hematogenous disorder are all at a high risk for opportunistic fungal infections. In addition, certain age groups such as infants, the elderly, and pregnant women are at a higher risk of oral fungal infections.
Mechanical trauma from an ill-fitted prosthesis is also a major cause of oral microfungal infections. One report estimated that Cand;da was involved in 60% of the cases of "denture sore mouth" (denture stomatitis) in the elderly (Budtz-Jorgensen, E. et al., CommunitY Dent. Oral E~idemiol.
Many factors can predispose a patient to an opportunistic microfungal infection in the oral cavity. For example, general debilitation or poor oral hyg;ene are predisposing factors. Patients who are being treated with antibiotics, steroids, or cytostatic therapy, patients with AIDS, diabetes mellitus or other immunodeficiency or hormonal diseases, patients with malignant tumors or a hematogenous disorder are all at a high risk for opportunistic fungal infections. In addition, certain age groups such as infants, the elderly, and pregnant women are at a higher risk of oral fungal infections.
Mechanical trauma from an ill-fitted prosthesis is also a major cause of oral microfungal infections. One report estimated that Cand;da was involved in 60% of the cases of "denture sore mouth" (denture stomatitis) in the elderly (Budtz-Jorgensen, E. et al., CommunitY Dent. Oral E~idemiol.
3:115 (1975))- Denture stomatitis appears to be a manifestation of a cell-mediated hypersensitivity reaction to the microfungal infection.
It is important to treat oral mycotic infections as soon as possible. Untreated infections may become the foci for systemic dissemination of the yeast or fungus, with potentially fatal results in severely compromised patients.
For example, disseminated candidosis is the second most common opportunistic infection in patients with AIDS (Odds, F.C., CRC
Crit. Rev. Microbiol. 15:1-5 (1937)~.
The most important species of microfungi which have been implicated as being involved in superficial or deep mycotic infections in the oral cavity include Candida albicans, C.
tropicalis, C. stellatoidea, C. pseudotropicalis, C.
Darapsilosis, C. quilliermondii, C. krusei, and C.
vixwanathii, all of which have been implicated in candidosis;
ToruloDsis ulabrata which is the cause of torulpsidosis;
Geotrichum candidum, which is the cause of geotrichosis;
-3- ~q~ 3~7~2 Rhizopus, Mucor, Absidia, and Bas;diobolus which are the cause of aspergillosis, CrYptococcus neoformans, the cause of cryptococcosis; Blastomyces dermatitid;s, the cause of blastomycosis; Paracocc;dioides brasiliensis, the cause of paracoccidioidomycosis; Sporothrix schenkii, the cause of sporotrichosis; Rhinosporidium seeberi, the cause of rhinosporidoisis; Histoplasma capsulatum, the cause of histoplasmos;s; HistoPlasma duboisi;, the cause of African histoplasmosis, Coccidiodes immities, the cause of coccidioidomycosis, TrichophYton mentaqrophvtes, T. rubrum, T.
tonsurans, and T. violaceum, the causes of dermatophytosis;
and, Rhinocladiella or PhialoPhora, and Cladosporium, the causes of chromomycosis.
The Candida species is the most virulent of the fungi which infect the oral mucosa. Pathogenic Candida species are aerobic yeasts that can also grow anaerobically. C. albicans, the Candida species most often responsible for infections of the oral cavity, grows in two morphological forms: either as a budding yeast, or as a continuously extending hyphae which extends into tissue. In the oral cavity, Candida may cause a variety of disorders based on localization of the infection such as pulpitis, gingivitis, tonsillitis, cheilitis, glossitis, stomatitis, pharyngitis, laryngitis and sinusit;s.
Oral cand;dos;s has been class;f;ed into d;fferent categories based on the cl;nical and histopathological manifestations of the infection (Lehner, T., in Clinical Aspects of immunoloqv, P.G.H. Gell, et al., eds., 3rd edition, Blackwell Scientific Publications, Oxford, 1975, pp.1387-1427).
Acute pseudomembranous candidosis, or thrush, primarily affects children or patients with debilitating diseases (Crawson, R.A., Dent. Res. 15:361-364 (1965). C. albicans is a major causative agent of thrush in the newborn.
It is important to treat oral mycotic infections as soon as possible. Untreated infections may become the foci for systemic dissemination of the yeast or fungus, with potentially fatal results in severely compromised patients.
For example, disseminated candidosis is the second most common opportunistic infection in patients with AIDS (Odds, F.C., CRC
Crit. Rev. Microbiol. 15:1-5 (1937)~.
The most important species of microfungi which have been implicated as being involved in superficial or deep mycotic infections in the oral cavity include Candida albicans, C.
tropicalis, C. stellatoidea, C. pseudotropicalis, C.
Darapsilosis, C. quilliermondii, C. krusei, and C.
vixwanathii, all of which have been implicated in candidosis;
ToruloDsis ulabrata which is the cause of torulpsidosis;
Geotrichum candidum, which is the cause of geotrichosis;
-3- ~q~ 3~7~2 Rhizopus, Mucor, Absidia, and Bas;diobolus which are the cause of aspergillosis, CrYptococcus neoformans, the cause of cryptococcosis; Blastomyces dermatitid;s, the cause of blastomycosis; Paracocc;dioides brasiliensis, the cause of paracoccidioidomycosis; Sporothrix schenkii, the cause of sporotrichosis; Rhinosporidium seeberi, the cause of rhinosporidoisis; Histoplasma capsulatum, the cause of histoplasmos;s; HistoPlasma duboisi;, the cause of African histoplasmosis, Coccidiodes immities, the cause of coccidioidomycosis, TrichophYton mentaqrophvtes, T. rubrum, T.
tonsurans, and T. violaceum, the causes of dermatophytosis;
and, Rhinocladiella or PhialoPhora, and Cladosporium, the causes of chromomycosis.
The Candida species is the most virulent of the fungi which infect the oral mucosa. Pathogenic Candida species are aerobic yeasts that can also grow anaerobically. C. albicans, the Candida species most often responsible for infections of the oral cavity, grows in two morphological forms: either as a budding yeast, or as a continuously extending hyphae which extends into tissue. In the oral cavity, Candida may cause a variety of disorders based on localization of the infection such as pulpitis, gingivitis, tonsillitis, cheilitis, glossitis, stomatitis, pharyngitis, laryngitis and sinusit;s.
Oral cand;dos;s has been class;f;ed into d;fferent categories based on the cl;nical and histopathological manifestations of the infection (Lehner, T., in Clinical Aspects of immunoloqv, P.G.H. Gell, et al., eds., 3rd edition, Blackwell Scientific Publications, Oxford, 1975, pp.1387-1427).
Acute pseudomembranous candidosis, or thrush, primarily affects children or patients with debilitating diseases (Crawson, R.A., Dent. Res. 15:361-364 (1965). C. albicans is a major causative agent of thrush in the newborn.
-4- ~0 0 8 7 7 The clinical signs which usually appear first are creamy-white, soft, nonkeratotic plaques which appear on the mucosa of the tongue, cheeks, gum and pharynx. The plaque is eas;ly rubbed off, leaving an inflamed mucosa underneath. There may be no subjective symptoms until the plaque spreads to the pharynx, larynx or esophagus, where it may cause dysphaghia, soreness and dryness of the tongue, a sore throat or symptoms of che;lit;s.
Acute atroph;c cand;dosis ;s a form of thrush which is cons;stently painful, and wh;ch ;s thought to ar;se as a consequence of the shedd;ng of the fungal plaque from its site of attachment to the tissue. It can be found on the dorsum l;nguae, or assoc;ated with angular cheilit;s and inflam~at;on of cheeks and lips.
Chron;c atroph;c candidosis, or denture stomatitis is the term given to Candida-based infections of the denture-bearing tissues. Torulopsis glabrata is also associated with some forms of denture stomatitis.
Chronic mucocutaneous candidosis refers to four different types of candidosis which are resistant to treatment and wh;ch are asscciat~d with patients with a heterogeneous pattern of immunodeficiencies. These types of candidosis include chronic oral hyperplastic candidosis, which predominately affects adult males between the ages of 30 and 70; chron;c localized mucocutaneous candidosis, which starts in childhood as an intractable oral Candida in~ection and later man;fects itself as lesions in the nails, and skin of the fingers and toes;
chronic localized mucocutaneous candidosis with granuloma which primarily affects young girls, s~arting in the mouth but later manifesting itself as horny masses of the face, scalp and upper respiratory tract; and, chronic localized mucocutaneous chadidosis with endocrine disorder, also found most frequently in young girls, and associated with lesions of the tongue, cheek, oral commissures and na~ls.
Acute atroph;c cand;dosis ;s a form of thrush which is cons;stently painful, and wh;ch ;s thought to ar;se as a consequence of the shedd;ng of the fungal plaque from its site of attachment to the tissue. It can be found on the dorsum l;nguae, or assoc;ated with angular cheilit;s and inflam~at;on of cheeks and lips.
Chron;c atroph;c candidosis, or denture stomatitis is the term given to Candida-based infections of the denture-bearing tissues. Torulopsis glabrata is also associated with some forms of denture stomatitis.
Chronic mucocutaneous candidosis refers to four different types of candidosis which are resistant to treatment and wh;ch are asscciat~d with patients with a heterogeneous pattern of immunodeficiencies. These types of candidosis include chronic oral hyperplastic candidosis, which predominately affects adult males between the ages of 30 and 70; chron;c localized mucocutaneous candidosis, which starts in childhood as an intractable oral Candida in~ection and later man;fects itself as lesions in the nails, and skin of the fingers and toes;
chronic localized mucocutaneous candidosis with granuloma which primarily affects young girls, s~arting in the mouth but later manifesting itself as horny masses of the face, scalp and upper respiratory tract; and, chronic localized mucocutaneous chadidosis with endocrine disorder, also found most frequently in young girls, and associated with lesions of the tongue, cheek, oral commissures and na~ls.
-5- ;~0~37 7 Z
The establishment of a mycotic infection in the oral cavity presents a serious health problem to the host which must be treated and contained. Treatment of mycotic diseases is directed to controll;ng th;s flora.
The most widely used approach to date to control m;crofung; in the oral cavity has been mechan;cal cleaning methods such as brush;ng the teeth. Although th;s method has proved to be fairly successful in treating individuals, there ;s still a h;gh recurrence rate. There ;s also the problem of mot;vat;ng people to good oral hygiene habi$s that they w;ll ma;ntain throughout their lives.
System;c adm;nistration of antimycotics ~ os or intravenously has been used to control mycot;c infections, however, d;scontinuation of therapy often results ;n the return of the pathogens to the oral cav;ty. Long-term systemic antimycot;c therapy ;n doses high enough to control oral infections are undesirable for treatment of oral infections because the potential dangers and side-effects associated with this form of treatment include the development of resistant strains and superimposed infections, gastrointestinal irritation, liver damage and neurological symptoms, among others.
Antifungal agents have also been used in the form of mouth rinses, dentifrices, solutions and gels but have not proven to be completely successful in preventing fungal infections. A main problem w;th these techniques is that the antifungal drug does not remain in the oral ca~ity long enough at efficacious levels.
Another serious problem with antifungal drugs is that they are by necessity directed towards controlling an infection by a eukaryotic fungal cell in a eukaryotic host.
As a result, drugs effective against the fungus also tend to be toxic to the host. Thus is it important to develop methods which permit the localized, sustained application of the toxic -6- 2~30 drug in a manner and dosage which is efficacious but which minimizes toxicity the host. Especially, it is important to develop methods which use low doses of the drug.
A topical, sustained-release form of an antifungal agent, could help maintain a locally efficacious level of the antifungal drug ;n the oral cavity and prevent these side effects. Such a dosage form might also prevent undesirable systemic side effects by releasing the drug at a lower therapeutic level over a long period of t;me in a localized manner. Ridgway, F. et al., U.S. 4,725,440, describes a soft, antifungal drug-containing pastille or troche which is free of rough edges and will not adhere to oral mucosa, but which only releases anti-fungal medications within the 15-90 minutes while it dissolves ;n the mouth.
Cyr et al., US 3,312,594 describes long lasting troches or pastilles for the treatment of oral lesions which include an anhydrous adhesive based on pectin, gelatin and carboxymethylcellulose and which~ when wetted, adhere to the oral mucous membranes. However9 the Cyr formulation was not well-tolerated by patients (Ridgway, F. et al., U.S.
4,725,440)-Sustained release has been reported to be achieved by embedding chlorhexidine in an ethyl cellulose polymer to form a varnish (Friedman, M., et al., J. Perio. Res. 17:323 328 (1982); Friedman, M., et al., IADR Prog. and Abstr. 59:No. 905 (1980)). This dosage form was used in the local treatment of periodontal disease (Soskolne, W.A., et al., J. Perio._Res.
18:330-336 (1983)) and in the treatment of plaque prevention in patients wearing orthodont;c appliances (Friedman, M., et al., J. Dent. Res. 64:1319-1321 (1985)). A drawback to this plaque preventat;ve system was that although plaque accumula-tion was decreased by the application of a varnish composed of chlorhexidine embedded in an ethyl cellulose polymer, the effectiveness of the system in decreasing plaque accumulation -7- 200~3772 was present only for a period of four days subsequent to administration of the varnish. Friedman et al.~ (J. Dent.
Res., supra)? concluded that ~clearly the conditions in the oral cavity and the formulation used do not, at present, facilitate such prolonged prevention of plaque accumulation."
These authors also suggested that by altering the varnish components and method of preparation it might be possible in clin;cal use to sustain the necessary level of antibacterial agent release for longer per;ods. No suggestion was made in this publication as to how this could be accomplished.
Mastic has been used previously for dental purposes.
U.S. Patent No. 4,668,18~ (Wolfenson, G.B.) discloses the use of a curable mastic in the production of an oral impress;on tray for making impressions of teeth and jaw structures.
Mastics have been used in the production of dental molds (U.S.
Patent No. 4,500,288, VonWeissenfluh, H.), as an adhesive to secure dental articulators (U.S. Patent Nos. 4,548,581 and 4,382,787, Hoffman, R.E.) and as a tooth decay preventative (U.S. Patent No. 4,374,824 9 Wahmi). U.S. Patent Nos. 4,532,126 and 4,428,927 (Ebert, W.R., et al.) disclose chewable, filled, one-piece soft elastic gelatin capsules, made chewable by a masticatory substance, such as a synthetic mastic.
U.S. Patent No. 4,459,277 (Kosti, C.M.) relates to novel plaque compositions for use in evaluating oral hygiene practices. In brief, the patent discloses a water-insoluble, water-immiscible dye emulsified in fine droplets or rupturable capsules. The patent discloses the use of mastic resin as well as alginates, and other gums as an insoluble media for dye dispersion. In particular, sodium carboxymethylcellulose is disclosed. Also disclosed is the possibility of incorporating antibacterial agents such as stannous fluoride into the compositions. Significantly, the Kosti patent is concerned with diagnsstic rather than th~rapeutic -8- 2(30~37~7~
applications. The patent fails to suggest compos;tions exhibi~ing l~ng-term preventive activity.
The background art fails to identify any compositions of matter comprising an effective antifungal agent together with a long-term sustained-release carrier, in combination with an adhesive polymer such as a mastic and a plasticizer such as polyethylene glycol, for use as an antifungal preventative varnish in the oral cavity by humans and other an;mals, under conditions in whi~h the antimycotic agents have no deleterious medical side effects, and do not cause staining of the teeth.
Another highly desirable characteristic not found in the art of record is that the antifungal agent should be released from the composition, not only in a sustained fashion, but over a sufficiently long period of time so as not to require excessive application of the compos;tion.
SUMMARY OF THE INVENTION
With this need in mind, the present inventor set out to find an oral antimycotic preventative composition which contains an antifungal agent effective against those microfungi that are responsible for oral infections, said composition being such that the antifungal agent can be released at efficacious levels in a sustained, long-term fashion, and such that the antifungal composition has the property of long-term adhesion to the oral tissue and teeth, and such that the antifungal composition remains plastic during the entire period of application. With this goal ;n mind, the inventor has d;scovered an antifungal preventative composition with these desirable characteristics, the composition comprising an antifungal agent embedded in a sustained release carrier composed of a cellulose polymer, in a pharmaceutically acceptable vehicle, optionally containing a 9 ~ (38 7~7 plasticizer such as polyethylene glycol and/or an adhesive polymer such as gum mastic.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
This invention relates to oral compositions that provide sustained, efficient, inexpensive, localized antifungal activity in the oral cavity at efficacious levels without deleterious side effects, and methods for using such compositions.
By "oral cavity" is meant the mouth and the surrounding esophageal area. Therefore, for example, the oral cavity includes the tongue, gums, palate, throat, teeth, tonsils and periodontal tissue.
By "sustained-release" is meant the continuous release of an active substance at effi~ac;ous levels for a prolonged period of time, such as 2-4 weeks or longer. The release of the active substance may be constant or pulsed, as long as efficacious levels of the active substance are provided to the surrounding milieu for the desired period of time.
By an "efficacious level" is meant a level or concentration of a drug or other active agent which is high enough to be effective in treating the condition the drug was designed to treat.
By "oral varnish" is meant a composition which is topically applied to a hard surface such as a tooth or orthodontic appliance and which dries as a film adhering to that surface, in a manner which resists removal under normal conditions, such as eating or brushing the teeth.
The compilation of the components of the aforementioned oral composition is based upon the specific properties of each of the individual components, wherein each component of the combination increases the antifungal effectiveness of other members of the combinat;on.
The establishment of a mycotic infection in the oral cavity presents a serious health problem to the host which must be treated and contained. Treatment of mycotic diseases is directed to controll;ng th;s flora.
The most widely used approach to date to control m;crofung; in the oral cavity has been mechan;cal cleaning methods such as brush;ng the teeth. Although th;s method has proved to be fairly successful in treating individuals, there ;s still a h;gh recurrence rate. There ;s also the problem of mot;vat;ng people to good oral hygiene habi$s that they w;ll ma;ntain throughout their lives.
System;c adm;nistration of antimycotics ~ os or intravenously has been used to control mycot;c infections, however, d;scontinuation of therapy often results ;n the return of the pathogens to the oral cav;ty. Long-term systemic antimycot;c therapy ;n doses high enough to control oral infections are undesirable for treatment of oral infections because the potential dangers and side-effects associated with this form of treatment include the development of resistant strains and superimposed infections, gastrointestinal irritation, liver damage and neurological symptoms, among others.
Antifungal agents have also been used in the form of mouth rinses, dentifrices, solutions and gels but have not proven to be completely successful in preventing fungal infections. A main problem w;th these techniques is that the antifungal drug does not remain in the oral ca~ity long enough at efficacious levels.
Another serious problem with antifungal drugs is that they are by necessity directed towards controlling an infection by a eukaryotic fungal cell in a eukaryotic host.
As a result, drugs effective against the fungus also tend to be toxic to the host. Thus is it important to develop methods which permit the localized, sustained application of the toxic -6- 2~30 drug in a manner and dosage which is efficacious but which minimizes toxicity the host. Especially, it is important to develop methods which use low doses of the drug.
A topical, sustained-release form of an antifungal agent, could help maintain a locally efficacious level of the antifungal drug ;n the oral cavity and prevent these side effects. Such a dosage form might also prevent undesirable systemic side effects by releasing the drug at a lower therapeutic level over a long period of t;me in a localized manner. Ridgway, F. et al., U.S. 4,725,440, describes a soft, antifungal drug-containing pastille or troche which is free of rough edges and will not adhere to oral mucosa, but which only releases anti-fungal medications within the 15-90 minutes while it dissolves ;n the mouth.
Cyr et al., US 3,312,594 describes long lasting troches or pastilles for the treatment of oral lesions which include an anhydrous adhesive based on pectin, gelatin and carboxymethylcellulose and which~ when wetted, adhere to the oral mucous membranes. However9 the Cyr formulation was not well-tolerated by patients (Ridgway, F. et al., U.S.
4,725,440)-Sustained release has been reported to be achieved by embedding chlorhexidine in an ethyl cellulose polymer to form a varnish (Friedman, M., et al., J. Perio. Res. 17:323 328 (1982); Friedman, M., et al., IADR Prog. and Abstr. 59:No. 905 (1980)). This dosage form was used in the local treatment of periodontal disease (Soskolne, W.A., et al., J. Perio._Res.
18:330-336 (1983)) and in the treatment of plaque prevention in patients wearing orthodont;c appliances (Friedman, M., et al., J. Dent. Res. 64:1319-1321 (1985)). A drawback to this plaque preventat;ve system was that although plaque accumula-tion was decreased by the application of a varnish composed of chlorhexidine embedded in an ethyl cellulose polymer, the effectiveness of the system in decreasing plaque accumulation -7- 200~3772 was present only for a period of four days subsequent to administration of the varnish. Friedman et al.~ (J. Dent.
Res., supra)? concluded that ~clearly the conditions in the oral cavity and the formulation used do not, at present, facilitate such prolonged prevention of plaque accumulation."
These authors also suggested that by altering the varnish components and method of preparation it might be possible in clin;cal use to sustain the necessary level of antibacterial agent release for longer per;ods. No suggestion was made in this publication as to how this could be accomplished.
Mastic has been used previously for dental purposes.
U.S. Patent No. 4,668,18~ (Wolfenson, G.B.) discloses the use of a curable mastic in the production of an oral impress;on tray for making impressions of teeth and jaw structures.
Mastics have been used in the production of dental molds (U.S.
Patent No. 4,500,288, VonWeissenfluh, H.), as an adhesive to secure dental articulators (U.S. Patent Nos. 4,548,581 and 4,382,787, Hoffman, R.E.) and as a tooth decay preventative (U.S. Patent No. 4,374,824 9 Wahmi). U.S. Patent Nos. 4,532,126 and 4,428,927 (Ebert, W.R., et al.) disclose chewable, filled, one-piece soft elastic gelatin capsules, made chewable by a masticatory substance, such as a synthetic mastic.
U.S. Patent No. 4,459,277 (Kosti, C.M.) relates to novel plaque compositions for use in evaluating oral hygiene practices. In brief, the patent discloses a water-insoluble, water-immiscible dye emulsified in fine droplets or rupturable capsules. The patent discloses the use of mastic resin as well as alginates, and other gums as an insoluble media for dye dispersion. In particular, sodium carboxymethylcellulose is disclosed. Also disclosed is the possibility of incorporating antibacterial agents such as stannous fluoride into the compositions. Significantly, the Kosti patent is concerned with diagnsstic rather than th~rapeutic -8- 2(30~37~7~
applications. The patent fails to suggest compos;tions exhibi~ing l~ng-term preventive activity.
The background art fails to identify any compositions of matter comprising an effective antifungal agent together with a long-term sustained-release carrier, in combination with an adhesive polymer such as a mastic and a plasticizer such as polyethylene glycol, for use as an antifungal preventative varnish in the oral cavity by humans and other an;mals, under conditions in whi~h the antimycotic agents have no deleterious medical side effects, and do not cause staining of the teeth.
Another highly desirable characteristic not found in the art of record is that the antifungal agent should be released from the composition, not only in a sustained fashion, but over a sufficiently long period of time so as not to require excessive application of the compos;tion.
SUMMARY OF THE INVENTION
With this need in mind, the present inventor set out to find an oral antimycotic preventative composition which contains an antifungal agent effective against those microfungi that are responsible for oral infections, said composition being such that the antifungal agent can be released at efficacious levels in a sustained, long-term fashion, and such that the antifungal composition has the property of long-term adhesion to the oral tissue and teeth, and such that the antifungal composition remains plastic during the entire period of application. With this goal ;n mind, the inventor has d;scovered an antifungal preventative composition with these desirable characteristics, the composition comprising an antifungal agent embedded in a sustained release carrier composed of a cellulose polymer, in a pharmaceutically acceptable vehicle, optionally containing a 9 ~ (38 7~7 plasticizer such as polyethylene glycol and/or an adhesive polymer such as gum mastic.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
This invention relates to oral compositions that provide sustained, efficient, inexpensive, localized antifungal activity in the oral cavity at efficacious levels without deleterious side effects, and methods for using such compositions.
By "oral cavity" is meant the mouth and the surrounding esophageal area. Therefore, for example, the oral cavity includes the tongue, gums, palate, throat, teeth, tonsils and periodontal tissue.
By "sustained-release" is meant the continuous release of an active substance at effi~ac;ous levels for a prolonged period of time, such as 2-4 weeks or longer. The release of the active substance may be constant or pulsed, as long as efficacious levels of the active substance are provided to the surrounding milieu for the desired period of time.
By an "efficacious level" is meant a level or concentration of a drug or other active agent which is high enough to be effective in treating the condition the drug was designed to treat.
By "oral varnish" is meant a composition which is topically applied to a hard surface such as a tooth or orthodontic appliance and which dries as a film adhering to that surface, in a manner which resists removal under normal conditions, such as eating or brushing the teeth.
The compilation of the components of the aforementioned oral composition is based upon the specific properties of each of the individual components, wherein each component of the combination increases the antifungal effectiveness of other members of the combinat;on.
-10~ 3()8 7 The oral composition of the invention assists in the prevention of microfungal infections of the oral cavity and periodontal tissue, and in the relief of symptoms result;ng from existing microfungally-caused problems, by attacking the pathogenic yeast and fungi responsible for the infection in the oral cavity. A variety of antifungal agents are suitable for the present invention. Preferred are the polyene antifungals, especially nystatin and amphotericin B.
Examples of other antifungal agents applicable to the methods of the ;nvention include 5-fluorocytosine and imidazole- and triazole-derivative antifungal agents, especially naftifine, terbinafine, tolnaftate, tolciclate, isoconazole, sulconazole, miconazole, clotrimazole, econazolet bifonazole, oxiconazole, tioconazole, ketoconazole, itraconazole, fluconazole, and terconazole, all known to the art. See, for example, Kostiala, I. qt al., Acta Odontol ! Scand. 37;87-101 (1979);
and Bossche, H.V., CRC Crit. Rev. Microbiol. 15:57 72 (1987).
In another embodiment, combinations of more than one antifungal agent are used in the composition of the inven~ion.
Combinations of an~ifungal agents can be prepared, for example, for the purpose of providing treatment or protection against a broad spectrum of microfungal species, or for the purpose of attacking a specific microfungal species with drugs acting through different modes of action. Combinat;on of antifungal agents may also allow a lower dose of a given antifungal agent to synergist;cally act with a lower dose of another antifungal agent in a manner which is efficacious in combination but not separately.
The antimycotic composition may be formulated to include other drugs such as antibacterial or antiseptic agents known to the `art. See, for example, the section on l'Quaternary Ammonium and Related Compounds" in the article on "Antiseptics and Disinfectants" in Kirk-Othmer Encyclopedia of Chemical Technology, 2nd ed. (VQ1. 2, PP. 632-5), incorporated herein ~ 0 by reference. Such materials have been used in oral compositions to counter bacteria in the oral cavity. Among the most common and efficacious of these antibacterial, quaternary am~onium compounds are cetylpyridinium chloride and benzalkonium chloride. Other cationic ammonium antibacterial agents of this type are mentioned, for instance, in U.S.
Patent Nos. 2,984,639, 3,325,402, 3,431,208, 3,703,583, and 4,339,430, British Patent No. 1,319,396, and German Patent No.
2,332,383. Most preferred is cetylpyridinium chloride, which is efficacious, compatible with the other components of the oral composition, and inexpensive by virtue of being a non-prescription drug. None of these compounds has been used before in sustained release, long-acting compositions. By long acting is meant a compos;tion which provides eff;cacious levels of the act;ve drug conta;ned there;n for a per;od of weeks, preferably at least 4 weeks, or 30 days.
It is also a feature of this invention that the aforementioned antifungal agent is released to the sites of fungal lesions and pockets in a long-term sustained release manner so as to reduce the required frequency of use. Long-term sustained release is desirable because it improves patient compliance with the treatment protocol and it is more convenient for the patient. Hence the success of the treatment is more probable. The method of the invention needs only a s;ngle application of the oral varnish composition of the invention to remain efficacious for a per;od of weeks.
Other methods require a multi-dose application of paste every few days or ingestion of lozenges every four hours by the patient. At best? the pastes rema;n effective for 2-3 days and the lozenges only for hours.
In addition, by the composition and method of the invention, because of the long-term sustained release of the drug, much lower amounts of the antifungal drug are required for efficacious results. Conventional therapy uses doses of nystatin as high as 108IU/dose. The concentrations of nystatin preferred in the invention are 2X105 I.U., with an acceptable range of 2X105-106 I.U. Because of the lower doses of nystatin, the side effects of the drug are eliminated or minimized. For example, at the efficacious concentrations of nystatin taught by the compositions and methods of the invention, in clin;cal evaluations there was no bitter-taste noted. The bitter taste of the drug is one of the major complaints of patients taking conventional nystatin therapy.
Lastly, the physical form and manner of presentation of the composition of the invention is highly advantageous for a patient with an oral microfungal infection. Often the area of the infection is so sore so as to make the direct application of a paste or even suck;ng lozenges, troches or pastilles very painful; rinsing with a mouthwash does not leave efficacious levels of the drug in the oral cavity. In other cases, oral treatments with mouthwashes, lozenges, pastes, troches or pastilles is very difficult or just not practical, for example with infants or animals. The cnmpositions and methods of the invention solve this problem by applying the antifungal drug to the teeth, gingival tissues or orthodontic appliance, for slow, long-term sustained release at efficacious levels into the salival fluids of the oral cavity. In addition the composition of the invention is colorless and visually undetectable by those unaware of the treatment.
Long term sustained release is accomplished by embedding the active drug agent(s) in a polymer. The specific polymer used is not critical. Long term sustained release, may, in accordance with the present invention, be accomplished by embedding an anti-fungal agent in any biologically suitable polymer. For example, a hydrophobic polymer, a hydrophilic polymer, or a combination of hydrophilic and hydrophobic polymers, may be used to form sustained releases formulations that would be suitable as a varnish for oral administration in ~o accordance with the present invention. One or more proteina-ceous polymers (such as gelatin, etc.), cellulosic polymers, acrylic polymers, etc. may be employed. Suitable polymers are disclosed in U.S. Patent Applications Serial Nos. 07/189,91~3;
07/304,091; 07/369,223; and 07/432,667; which applications are herein incorporated by reference in their entirety.
Cellulosic or acrylic polymers are especially preferred for forming a varnish for oral administration. The use of these polymers provides the advantage of allowing lower doses of a drug to be used and thus eliminating or minimizing side effects such as staining of teeth and dentures and unpleasant taste. A variety of suitable hydrophobic polymers are known in the art of oral compositions. Preferred are the insoluble and inexpensive polymers: hydrophobic type (poly-ethylene, polymethacrylate, polyamide-nylon, poly(ethylene-vinyl acetate) cellulose nitrate, silicones and others). Mosk preferred is ethyl cellulose. Another suitable polymer is methylacrylic acid polymer.
The composition of the invention is preferably applied to teeth or dental appliances which act as a solid support and point of release for the antifungal agent in the composition throughout the treatment period. The tooth or orthodontic appliance varnished with the antifungal composition of the invention may be placed in direct contact with the site of infection, as for example, by placing dentures on top an infected or irritated gum for the treatment of d~nture stomatitis. Alternatively, the varnished tooth or dental appliance may act as a reservoir which releases efficacious levels of the antifungal agent in the salival fluids to other infected sites within the oral cavity or throat. Therefore, in a h;ghly preferred embodiment, there is direct contact between the composition of the invention and the site of microfungal infection. In another preferred embodiment, the composition of the invention is applied to a site removed from ~ 37 the infected area but wi~hin the range of the efficacious levels of antifungal drugs released by said composition.
Orthodontic appliances within the scope of the invention include dentures, bridges, braces, anchoring pins and the like. The appliance can be a temporary as permanent appliance. The compos;tions and methods of the present invention therefore provide a therapy for denture stomatitis, oral thrush, and other oral fungal diseases and conditions.
Thus, in a preferred embodiment, an oral composition with the highly desirable characteristics mentioned above comprises an antimycotic compound such as nystatin embedded in a sus-tained release cellulosic polymer such as ethyl cellulose, in a pharmaceutically effective vehicle. For example, nystatin, 100,000 IU (1-5 parts), and ethyl cellulose (5-9 parts) may be dissolved in ethanol (80-120 parts) for the preparation of sustained release varnish in film form.
For application to buccal and lingual surfaces of teeth, an ethanolic solution of the antimycotic agent and cellulosic polymer (containing up to 4% of the drug as used in the varnish) are applied with a soft brush or with a spray.
Ethanol may be evaporated by a gentle stream of warm air.
Mouthwash forms are not suitable because of inefficient application of the composition to affected tissue areas.
However, orthodontic appliances such as dentures may be dipped in a solution containing the composition of the invention.
For application to orthodontic appliances, a total of about 40 mg of antimycotic agent such as nystatin or amphotericin B in an ethanolic solution with ethyl cellulose may be applied per appliance by dipping, spraying or painting it on with a soft brush, an~ residual solvent removed with a gentle stream of warm air.
Those skilled in the treatment o~ diseases of the oral cavity will, without undue experimentation, be able to produce -15- ~C)~8~7 ranges o~ concentrations of other appropriate antifungal agents and sustained release polymers.
The thickness of the film as varnish can be var;ed according to the desired length of efficacious treatment or drug potency. In a preferred embodiment the f;lm coating the tooth or appl;ance ;s 10-300 ~m thick.
It is another feature of the invent;on that the oral compositions for treatment and prevention of fungal infections also provide for add;t;onal desirable components. ~or example, the adhesiveness of the oral composition may be improved by the incorporation within said composition of gums such as gum mastic in a formulation providing from 1-20% by weight of the gum mastic. Other suitable mastics are disclosed in U.SO Pa~ent No. 4,315,779 to Heyd, D., et al., and U.S. Patent No. 4,374,~44 to Wahmi, H.V.R., et al.
In another formulation, other compositions may include demulcents/humectants (i.e., plast;cizers) such as polyethylene glycol 400-to-4000, glycerol, sorbitol, or mineral oil in concentrations of about 1% by weight. Other humectants, detergents, or surface-active agents will be known to those skilled in the formulation of oral compositions.
Thus, in a preferred composition, the oral composition of the invention comprises nystatin, ethyl cellulose polymer, an adhesive, a plasticizer, and solvent (i.e., aqueous ethanol).
In a highly preferred formulation, gum mastic is also present.
Water, flavorings, and coloring agents may also be present as required. Once applied to teeth or other orthodontic appliance, the varnish is not eas;ly removed by normal dental hygiene protocols, such as brush;ng. The dry film can only be removed mechanically. In addition, because the varnish coats the surface of the teeth or orthodontic support with a smooth surface and the same contours of the support, it adds no uncomfortable, unfamiliar or otherwise annoying geometry to the oral cavity, in the manner that a paste can.
z~q~
The composition and methods of the invention may also be applied as a preventative or deterrent measure, especially in patients highly susceptible to opportunistic infections of the oral cavity by microfungi.
The varnish of the invention may also be applied extraorally to sites of microfungal infection, for example, to infected nails on the fingers and toes of patients with chr~nic mucocutaneous candidosis. Alternatively, the composition of the invention, especially in combination with antibacterial agents, may be provided on a varnished pad or bandage or patch which is placed in contact with the site of infection, for example, topically or intravaginally.
Having now generally described the invention, the same will become better understood by reference to certain specific examples which are included herein for purposes of ;llustration only and are not intended to be limiting unless otherwise specified.
Example 1 Varnish Preparation The following formulations (Table 1) were all prepared by the same general procedure as follows: ethyl cellulose and polyethylene glycol polymers were dissolved in the suitable solvent. After complete dissolution of the polymers, the additional co~ponents of the varnish are added.
~ 3~37 Ethyl cellulose - EC
Polyethylene glycol - PEG
Nystatin - NYS
MATERIAL/FORMULATION
II III IV V VI VII VIII IIX X
NYS (G) 1.5 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 4.0 EC-NF100 (G) 8.5 7.0 6.0 6.0 6.0 5.0 6.0 6.0 6.0 6.0 PEG 400 (G) 0.5 1.0 1.0 1.0 1.0 1.0 --- --- --- ---PEG 4000 (G) --- --- --- --- --- --- 1.0 1.0 --- ---GUM MASTIC --- --~ -- 1.0 --- --- 1.0 ---ETHANOL (C"C) 100 100 100 80 120 100 100 100 100 100 Example 2 Evaluation of the Varnish in Vitro Sustained Release ActivitV of NYstatin on Candida Albicans in Vitro Films containing Nysta~in were cast from the varnish formulation IV on glass plates using the technique of Konig et al., J Pharm. Sci. 51:77 (1962). The solvent was allowed to -evaporate at room temperature and the residual film removed from the plate. A stra;n of C. albicans isolated from clinical material was used in the this study. A 1:10 dilution of an overnight growth stock suspension of the above organism was mixed with mycolog;cal culture medium (Sabourand) and poured into petri dishes. Five mm diameter disks of the films containing Nystatin were placed on the hardened medium.
After 24 h or 48 h, films were transferred onto another set of petri dishes containing the same medium plus C.
albicans suspension as in the first set.
Inhibition zones were recorded after incubation periods of 24 and 48 h at 37C. All films were used in dupl icate.
The mean inhibition zone is summarized in Table 2.
2~38772 Inhibition 70ne of Candida Growth bv Sustained Release Films Containinq NYstatin 5 Time (days) l 2 3 4 5 7 9 11 13 l~ 17 19 21 ~3 25 27 29 31 Inhibition 20 17 17 12 ll 12 13 13 ll ll lO 12 lO 10 9 10 9 9 zone (mm) There was no inhibition of Candida growth in control samples containing ethyl cellulose films only. The measurements of inhibition were discontinued after 31 days.
Example 3 Cinical StudY: Evaluation of the Varnish in viYo Preparation of coated denture. The Nystatin varnish (Formulation IV) was applied to the denture base facing the mucosa, by means of a soft brush. Removal of the solvent was achieved by a gentle stream of hot air.
The dentures were weighted before and after coating and the total amount of coating calculated. Forty mg of Nystat;n per denture was the average amount of drug used. (Equivalent to 200, 000 I . U . ) In the preliminary clinical evaluation of the system, 5 patients suffering from denture stomatitis were selected from an old age home. Three tests were performed on each patient:
a) 1 swab from upper gum, b~ 1 swab from denture, and c) 2 ml of saliva was collected.
Material from the swabs was washed into a solution containing 0.2% neopeptone ~ 0.8% Tween 80, which was also used for further dilution of this material and of the saliva.
Ten ml aliquots of the various dilutions were inoculated in ~ 3~7t7~
duplicate onto plates containing bacteriological blood agar (for bacterial isolation) and plates containing mycological medium Sabourand (for C. albicans isolation).
All plates were incubated for 48 h at 37C and the number of bacterial and yeast colonies recorded.
The effects of the local application of a sustained-release delivery system of nystatin on fungal growth due to denture stomatitis in these patients are summarized in Table 3.
In summary there was an improvement in clinical status of the disease was observed, total elimination of Candida in saliva, gum and denture with no change in the normal bacteria flora levels. There was an improved compliance on the part of the patient; one sinyle application is a much more ConYenient way of treatment compared to the conventional multi-dose application, and this new way of treatment is not dependent on the patient's cooperation.
Much lower amounts of Nystat;n are necessary for the clinical effect as compared to the total of 108 I.U. used in conventional therapy. Lastly, no side effects, such as the bitter taste of Nystatin were observed in the preliminary clinical evaluation of this system.
These results are consistent with inhibition of fungal growth in the oral cavity of these patients by this form of the drug and further suggest that efficacious concentrations of the drug on the tooth/tissue surface is achieved creating a local antimycotic effect.
.. ,~ V ~ ~ o o - o o ,,, o o . o V ~
_ __ U oO~O~o _ - ,~ o v " . ' -' . ..
ยข ~ O O ~ O O O O ~ O L- ~ O O ~ .
.~ . ~ .' ;' o~_ ~o~o~`o ~`o o~o~o~o~~ ~o~ ~o ~o~o~o _ ~ O v~ o ~o ~, ..
-o o o ~ ~. o ~ o o - ~ o ~ o o. ~ ., ~- -I '` ~~'` ~'`--~-- ~~ ~~ u ..
_ ~ # X >~ >~ Y K >~ 't # # K K .~ O
5~ u ,~ . o .. ~ . ~
~o _ _. o o ~ ~ ~ o ~ - I
~5 Vl ~ ,.. I , u _ "Oro"o ~o'o~O, ~o~ oO ~0~04~0 . L e _ _ _ -- ~ ~ O ~
. ~~ t~ o ~ o v~ O ~ ~ n v~
_ .
-21- ~ C~37~7z Having now fully described the invention, it w;ll be understood by those with skill in the art that the scope may be performed within a wide and equivalent range of conditions, parameters and the like, without affecting the spirit or scope of the invention or any embodiment thereof.
Examples of other antifungal agents applicable to the methods of the ;nvention include 5-fluorocytosine and imidazole- and triazole-derivative antifungal agents, especially naftifine, terbinafine, tolnaftate, tolciclate, isoconazole, sulconazole, miconazole, clotrimazole, econazolet bifonazole, oxiconazole, tioconazole, ketoconazole, itraconazole, fluconazole, and terconazole, all known to the art. See, for example, Kostiala, I. qt al., Acta Odontol ! Scand. 37;87-101 (1979);
and Bossche, H.V., CRC Crit. Rev. Microbiol. 15:57 72 (1987).
In another embodiment, combinations of more than one antifungal agent are used in the composition of the inven~ion.
Combinations of an~ifungal agents can be prepared, for example, for the purpose of providing treatment or protection against a broad spectrum of microfungal species, or for the purpose of attacking a specific microfungal species with drugs acting through different modes of action. Combinat;on of antifungal agents may also allow a lower dose of a given antifungal agent to synergist;cally act with a lower dose of another antifungal agent in a manner which is efficacious in combination but not separately.
The antimycotic composition may be formulated to include other drugs such as antibacterial or antiseptic agents known to the `art. See, for example, the section on l'Quaternary Ammonium and Related Compounds" in the article on "Antiseptics and Disinfectants" in Kirk-Othmer Encyclopedia of Chemical Technology, 2nd ed. (VQ1. 2, PP. 632-5), incorporated herein ~ 0 by reference. Such materials have been used in oral compositions to counter bacteria in the oral cavity. Among the most common and efficacious of these antibacterial, quaternary am~onium compounds are cetylpyridinium chloride and benzalkonium chloride. Other cationic ammonium antibacterial agents of this type are mentioned, for instance, in U.S.
Patent Nos. 2,984,639, 3,325,402, 3,431,208, 3,703,583, and 4,339,430, British Patent No. 1,319,396, and German Patent No.
2,332,383. Most preferred is cetylpyridinium chloride, which is efficacious, compatible with the other components of the oral composition, and inexpensive by virtue of being a non-prescription drug. None of these compounds has been used before in sustained release, long-acting compositions. By long acting is meant a compos;tion which provides eff;cacious levels of the act;ve drug conta;ned there;n for a per;od of weeks, preferably at least 4 weeks, or 30 days.
It is also a feature of this invention that the aforementioned antifungal agent is released to the sites of fungal lesions and pockets in a long-term sustained release manner so as to reduce the required frequency of use. Long-term sustained release is desirable because it improves patient compliance with the treatment protocol and it is more convenient for the patient. Hence the success of the treatment is more probable. The method of the invention needs only a s;ngle application of the oral varnish composition of the invention to remain efficacious for a per;od of weeks.
Other methods require a multi-dose application of paste every few days or ingestion of lozenges every four hours by the patient. At best? the pastes rema;n effective for 2-3 days and the lozenges only for hours.
In addition, by the composition and method of the invention, because of the long-term sustained release of the drug, much lower amounts of the antifungal drug are required for efficacious results. Conventional therapy uses doses of nystatin as high as 108IU/dose. The concentrations of nystatin preferred in the invention are 2X105 I.U., with an acceptable range of 2X105-106 I.U. Because of the lower doses of nystatin, the side effects of the drug are eliminated or minimized. For example, at the efficacious concentrations of nystatin taught by the compositions and methods of the invention, in clin;cal evaluations there was no bitter-taste noted. The bitter taste of the drug is one of the major complaints of patients taking conventional nystatin therapy.
Lastly, the physical form and manner of presentation of the composition of the invention is highly advantageous for a patient with an oral microfungal infection. Often the area of the infection is so sore so as to make the direct application of a paste or even suck;ng lozenges, troches or pastilles very painful; rinsing with a mouthwash does not leave efficacious levels of the drug in the oral cavity. In other cases, oral treatments with mouthwashes, lozenges, pastes, troches or pastilles is very difficult or just not practical, for example with infants or animals. The cnmpositions and methods of the invention solve this problem by applying the antifungal drug to the teeth, gingival tissues or orthodontic appliance, for slow, long-term sustained release at efficacious levels into the salival fluids of the oral cavity. In addition the composition of the invention is colorless and visually undetectable by those unaware of the treatment.
Long term sustained release is accomplished by embedding the active drug agent(s) in a polymer. The specific polymer used is not critical. Long term sustained release, may, in accordance with the present invention, be accomplished by embedding an anti-fungal agent in any biologically suitable polymer. For example, a hydrophobic polymer, a hydrophilic polymer, or a combination of hydrophilic and hydrophobic polymers, may be used to form sustained releases formulations that would be suitable as a varnish for oral administration in ~o accordance with the present invention. One or more proteina-ceous polymers (such as gelatin, etc.), cellulosic polymers, acrylic polymers, etc. may be employed. Suitable polymers are disclosed in U.S. Patent Applications Serial Nos. 07/189,91~3;
07/304,091; 07/369,223; and 07/432,667; which applications are herein incorporated by reference in their entirety.
Cellulosic or acrylic polymers are especially preferred for forming a varnish for oral administration. The use of these polymers provides the advantage of allowing lower doses of a drug to be used and thus eliminating or minimizing side effects such as staining of teeth and dentures and unpleasant taste. A variety of suitable hydrophobic polymers are known in the art of oral compositions. Preferred are the insoluble and inexpensive polymers: hydrophobic type (poly-ethylene, polymethacrylate, polyamide-nylon, poly(ethylene-vinyl acetate) cellulose nitrate, silicones and others). Mosk preferred is ethyl cellulose. Another suitable polymer is methylacrylic acid polymer.
The composition of the invention is preferably applied to teeth or dental appliances which act as a solid support and point of release for the antifungal agent in the composition throughout the treatment period. The tooth or orthodontic appliance varnished with the antifungal composition of the invention may be placed in direct contact with the site of infection, as for example, by placing dentures on top an infected or irritated gum for the treatment of d~nture stomatitis. Alternatively, the varnished tooth or dental appliance may act as a reservoir which releases efficacious levels of the antifungal agent in the salival fluids to other infected sites within the oral cavity or throat. Therefore, in a h;ghly preferred embodiment, there is direct contact between the composition of the invention and the site of microfungal infection. In another preferred embodiment, the composition of the invention is applied to a site removed from ~ 37 the infected area but wi~hin the range of the efficacious levels of antifungal drugs released by said composition.
Orthodontic appliances within the scope of the invention include dentures, bridges, braces, anchoring pins and the like. The appliance can be a temporary as permanent appliance. The compos;tions and methods of the present invention therefore provide a therapy for denture stomatitis, oral thrush, and other oral fungal diseases and conditions.
Thus, in a preferred embodiment, an oral composition with the highly desirable characteristics mentioned above comprises an antimycotic compound such as nystatin embedded in a sus-tained release cellulosic polymer such as ethyl cellulose, in a pharmaceutically effective vehicle. For example, nystatin, 100,000 IU (1-5 parts), and ethyl cellulose (5-9 parts) may be dissolved in ethanol (80-120 parts) for the preparation of sustained release varnish in film form.
For application to buccal and lingual surfaces of teeth, an ethanolic solution of the antimycotic agent and cellulosic polymer (containing up to 4% of the drug as used in the varnish) are applied with a soft brush or with a spray.
Ethanol may be evaporated by a gentle stream of warm air.
Mouthwash forms are not suitable because of inefficient application of the composition to affected tissue areas.
However, orthodontic appliances such as dentures may be dipped in a solution containing the composition of the invention.
For application to orthodontic appliances, a total of about 40 mg of antimycotic agent such as nystatin or amphotericin B in an ethanolic solution with ethyl cellulose may be applied per appliance by dipping, spraying or painting it on with a soft brush, an~ residual solvent removed with a gentle stream of warm air.
Those skilled in the treatment o~ diseases of the oral cavity will, without undue experimentation, be able to produce -15- ~C)~8~7 ranges o~ concentrations of other appropriate antifungal agents and sustained release polymers.
The thickness of the film as varnish can be var;ed according to the desired length of efficacious treatment or drug potency. In a preferred embodiment the f;lm coating the tooth or appl;ance ;s 10-300 ~m thick.
It is another feature of the invent;on that the oral compositions for treatment and prevention of fungal infections also provide for add;t;onal desirable components. ~or example, the adhesiveness of the oral composition may be improved by the incorporation within said composition of gums such as gum mastic in a formulation providing from 1-20% by weight of the gum mastic. Other suitable mastics are disclosed in U.SO Pa~ent No. 4,315,779 to Heyd, D., et al., and U.S. Patent No. 4,374,~44 to Wahmi, H.V.R., et al.
In another formulation, other compositions may include demulcents/humectants (i.e., plast;cizers) such as polyethylene glycol 400-to-4000, glycerol, sorbitol, or mineral oil in concentrations of about 1% by weight. Other humectants, detergents, or surface-active agents will be known to those skilled in the formulation of oral compositions.
Thus, in a preferred composition, the oral composition of the invention comprises nystatin, ethyl cellulose polymer, an adhesive, a plasticizer, and solvent (i.e., aqueous ethanol).
In a highly preferred formulation, gum mastic is also present.
Water, flavorings, and coloring agents may also be present as required. Once applied to teeth or other orthodontic appliance, the varnish is not eas;ly removed by normal dental hygiene protocols, such as brush;ng. The dry film can only be removed mechanically. In addition, because the varnish coats the surface of the teeth or orthodontic support with a smooth surface and the same contours of the support, it adds no uncomfortable, unfamiliar or otherwise annoying geometry to the oral cavity, in the manner that a paste can.
z~q~
The composition and methods of the invention may also be applied as a preventative or deterrent measure, especially in patients highly susceptible to opportunistic infections of the oral cavity by microfungi.
The varnish of the invention may also be applied extraorally to sites of microfungal infection, for example, to infected nails on the fingers and toes of patients with chr~nic mucocutaneous candidosis. Alternatively, the composition of the invention, especially in combination with antibacterial agents, may be provided on a varnished pad or bandage or patch which is placed in contact with the site of infection, for example, topically or intravaginally.
Having now generally described the invention, the same will become better understood by reference to certain specific examples which are included herein for purposes of ;llustration only and are not intended to be limiting unless otherwise specified.
Example 1 Varnish Preparation The following formulations (Table 1) were all prepared by the same general procedure as follows: ethyl cellulose and polyethylene glycol polymers were dissolved in the suitable solvent. After complete dissolution of the polymers, the additional co~ponents of the varnish are added.
~ 3~37 Ethyl cellulose - EC
Polyethylene glycol - PEG
Nystatin - NYS
MATERIAL/FORMULATION
II III IV V VI VII VIII IIX X
NYS (G) 1.5 2.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 4.0 EC-NF100 (G) 8.5 7.0 6.0 6.0 6.0 5.0 6.0 6.0 6.0 6.0 PEG 400 (G) 0.5 1.0 1.0 1.0 1.0 1.0 --- --- --- ---PEG 4000 (G) --- --- --- --- --- --- 1.0 1.0 --- ---GUM MASTIC --- --~ -- 1.0 --- --- 1.0 ---ETHANOL (C"C) 100 100 100 80 120 100 100 100 100 100 Example 2 Evaluation of the Varnish in Vitro Sustained Release ActivitV of NYstatin on Candida Albicans in Vitro Films containing Nysta~in were cast from the varnish formulation IV on glass plates using the technique of Konig et al., J Pharm. Sci. 51:77 (1962). The solvent was allowed to -evaporate at room temperature and the residual film removed from the plate. A stra;n of C. albicans isolated from clinical material was used in the this study. A 1:10 dilution of an overnight growth stock suspension of the above organism was mixed with mycolog;cal culture medium (Sabourand) and poured into petri dishes. Five mm diameter disks of the films containing Nystatin were placed on the hardened medium.
After 24 h or 48 h, films were transferred onto another set of petri dishes containing the same medium plus C.
albicans suspension as in the first set.
Inhibition zones were recorded after incubation periods of 24 and 48 h at 37C. All films were used in dupl icate.
The mean inhibition zone is summarized in Table 2.
2~38772 Inhibition 70ne of Candida Growth bv Sustained Release Films Containinq NYstatin 5 Time (days) l 2 3 4 5 7 9 11 13 l~ 17 19 21 ~3 25 27 29 31 Inhibition 20 17 17 12 ll 12 13 13 ll ll lO 12 lO 10 9 10 9 9 zone (mm) There was no inhibition of Candida growth in control samples containing ethyl cellulose films only. The measurements of inhibition were discontinued after 31 days.
Example 3 Cinical StudY: Evaluation of the Varnish in viYo Preparation of coated denture. The Nystatin varnish (Formulation IV) was applied to the denture base facing the mucosa, by means of a soft brush. Removal of the solvent was achieved by a gentle stream of hot air.
The dentures were weighted before and after coating and the total amount of coating calculated. Forty mg of Nystat;n per denture was the average amount of drug used. (Equivalent to 200, 000 I . U . ) In the preliminary clinical evaluation of the system, 5 patients suffering from denture stomatitis were selected from an old age home. Three tests were performed on each patient:
a) 1 swab from upper gum, b~ 1 swab from denture, and c) 2 ml of saliva was collected.
Material from the swabs was washed into a solution containing 0.2% neopeptone ~ 0.8% Tween 80, which was also used for further dilution of this material and of the saliva.
Ten ml aliquots of the various dilutions were inoculated in ~ 3~7t7~
duplicate onto plates containing bacteriological blood agar (for bacterial isolation) and plates containing mycological medium Sabourand (for C. albicans isolation).
All plates were incubated for 48 h at 37C and the number of bacterial and yeast colonies recorded.
The effects of the local application of a sustained-release delivery system of nystatin on fungal growth due to denture stomatitis in these patients are summarized in Table 3.
In summary there was an improvement in clinical status of the disease was observed, total elimination of Candida in saliva, gum and denture with no change in the normal bacteria flora levels. There was an improved compliance on the part of the patient; one sinyle application is a much more ConYenient way of treatment compared to the conventional multi-dose application, and this new way of treatment is not dependent on the patient's cooperation.
Much lower amounts of Nystat;n are necessary for the clinical effect as compared to the total of 108 I.U. used in conventional therapy. Lastly, no side effects, such as the bitter taste of Nystatin were observed in the preliminary clinical evaluation of this system.
These results are consistent with inhibition of fungal growth in the oral cavity of these patients by this form of the drug and further suggest that efficacious concentrations of the drug on the tooth/tissue surface is achieved creating a local antimycotic effect.
.. ,~ V ~ ~ o o - o o ,,, o o . o V ~
_ __ U oO~O~o _ - ,~ o v " . ' -' . ..
ยข ~ O O ~ O O O O ~ O L- ~ O O ~ .
.~ . ~ .' ;' o~_ ~o~o~`o ~`o o~o~o~o~~ ~o~ ~o ~o~o~o _ ~ O v~ o ~o ~, ..
-o o o ~ ~. o ~ o o - ~ o ~ o o. ~ ., ~- -I '` ~~'` ~'`--~-- ~~ ~~ u ..
_ ~ # X >~ >~ Y K >~ 't # # K K .~ O
5~ u ,~ . o .. ~ . ~
~o _ _. o o ~ ~ ~ o ~ - I
~5 Vl ~ ,.. I , u _ "Oro"o ~o'o~O, ~o~ oO ~0~04~0 . L e _ _ _ -- ~ ~ O ~
. ~~ t~ o ~ o v~ O ~ ~ n v~
_ .
-21- ~ C~37~7z Having now fully described the invention, it w;ll be understood by those with skill in the art that the scope may be performed within a wide and equivalent range of conditions, parameters and the like, without affecting the spirit or scope of the invention or any embodiment thereof.
Claims (21)
1. A sustained-release oral antifungal varnish composition which comprises:
(a) efficacious levels of an antimycotic drug and (b) a sustained release ethyl cellulose or hydrophobic polymer;
in a pharmaceutically acceptable vehicle.
(a) efficacious levels of an antimycotic drug and (b) a sustained release ethyl cellulose or hydrophobic polymer;
in a pharmaceutically acceptable vehicle.
2. The varnish composition of claim 1, wherein said antimycotic drug is selected from the group consisting of nystatin, amphotericin B, miconazole, and clotrimazole.
3. The varnish composition of claim 2, wherein said antimycotic drug is nystatin.
4. The varnish composition of claim 2, wherein said antimycotic drug is Amphotericin B.
5. The varnish composition of claim 19 wherein said sustained release hydrophobic polymer is selected from the group consisting of poly-ethylene, polymethacrylate, polyamide-nylon, poly(ethylene-vinyl acetate) cellulose nitrate, and silicones.
6. The varnish composition of claim 1, wherein said sustained release cellulosic polymer is ethyl cellulose.
7. The varnish composition of claim 1, wherein said pharmaceutically acceptable vehicle comprises an agent selected from the group consisting of water; ethyl alcohol;
and ethyl alcohol and water.
and ethyl alcohol and water.
8. The varnish composition of claim 7, which additionally contains an agent selected from the group consisting of a flavoring agent, surface active agent and coloring agent.
9. The varnish composition of claim 7, which additionally contains a plasticizer.
10. The varnish composition of claim 9, wherein said plasticizer is selected from the group consisting of polyethylene glycol, glycerol, sorbitol, and mineral oil.
11. The varnish composition of claim 7, which additionally contains an adhesive gum.
12. The varnish composition of claim 11, wherein said adhesive gum is gum mastic.
13. A method of treating microfungal infections of the oral cavity comprising application of the varnish composition of claim 1 to the teeth, gingival tissues or orthodontic appliance of an animal.
14. The method of claim 13, wherein said application is by brush.
15. The method of claim 13, wherein said application is by spray.
16. The method of claim 13, wherein said application is by dipping.
17. The method of claim 13, wherein said animal is a human.
18. The method of claim 13, wherein said animal is a domesticated animal.
19. The method of claim 13, wherein said microfungal infection is denture stomatitis and wherein said orthodontic appliance is a denture or set of dentures.
20. The method of claim 13, wherein said microfungal infection is selected from the group consisting of Candida and Torulopsis glabrata.
21. The method of claim 20, wherein said Candida is Candida albicans.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30409289A | 1989-01-31 | 1989-01-31 | |
US304,092 | 1989-01-31 | ||
US465,786 | 1990-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2008772A1 true CA2008772A1 (en) | 1990-07-31 |
Family
ID=23175014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2008772 Abandoned CA2008772A1 (en) | 1989-01-31 | 1990-01-29 | Oral antifungal preventative, and method of use |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2008772A1 (en) |
-
1990
- 1990-01-29 CA CA 2008772 patent/CA2008772A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0381446B1 (en) | Oral antifungal compositions | |
US5438076A (en) | Liquid polymer composition, and method of use | |
US5160737A (en) | Liquid polymer composition, and method of use | |
US4496322A (en) | Benzoin antimicrobial dental varnishes | |
US4981875A (en) | Medicaments for the region of the oral cavity | |
US5139768A (en) | Dental composition for hypersensitive teeth | |
RU2301056C2 (en) | Liquid polymeric composition for prophylaxis and treatment of mouth cavity disease | |
US10843013B2 (en) | Liquid precursor compositions and uses thereof for a ph-dependant sustained release treatment of oral disorders | |
AU2006206252B2 (en) | Methods and compositions for decreasing saliva production | |
Steinberg et al. | Dental drug-delivery devices: local and sustained-release applications | |
EP0381445B2 (en) | Dental composition for hypersensitive teeth | |
RU2184538C2 (en) | Use of dichlorobenzyl alcohol for preparing medicinal agent for treatment of topical inflammation and medicinal agent comprising dichlorobenzyl alcohol | |
CA2008772A1 (en) | Oral antifungal preventative, and method of use | |
US20140303101A1 (en) | Compositions for dental care | |
RU2809005C1 (en) | Oral care product containing hexapeptide and chlorhexidine | |
JPS62223114A (en) | Slowly-releasing remedy for periodontosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |